MODERNA

The story starts in a Harvard lab in 2009. Derrick Rossi, a stem cell researcher, figured out a way to use modified messenger RNA — the cellular instruction manual — to reprogram cells without permanently altering DNA.

He thought it was interesting. His colleagues thought it might be revolutionary.

He called Robert Langer, a legendary MIT bioengineer who had founded or co-founded more than 40 companies. Langer called Noubar Afeyan, a serial biotech entrepreneur who ran Flagship Pioneering, a firm that specialized in building companies around ideas most people thought were crazy.

Afeyan loved crazy. He loved mRNA specifically because it was theoretically elegant and practically untested.

If you could deliver synthetic mRNA into human cells reliably, you could essentially program the body to produce its own therapeutics — vaccines, cancer treatments, rare disease therapies. The body becomes the drug factory.

In 2010, they incorporated Moderna — a portmanteau of 'modified' and 'RNA.'

For the first eight years, Moderna was a mystery wrapped in NDAs. They raised enormous sums of money and told almost no one what they were doing.

They filed patents aggressively. They hired world-class scientists and paid them not to talk.

The biotech world was skeptical — mRNA had never been used to make an approved drug. The molecules were fragile, hard to deliver, and prone to triggering immune responses.

Stat News ran a brutal investigation in 2016 suggesting the science might not be working. Moderna didn't respond.

They just kept building.

By the time COVID-19 hit in January 2020, Moderna had been in stealth mode for a decade, burning through billions without a single approved product. Most people in pharma thought they were either deluded or running a very expensive science experiment.

Then the pandemic gave them the test case they'd been waiting for their whole existence.

The core business is discovering, developing, and commercializing mRNA-based medicines. Here's how it works: instead of injecting a weakened virus or a protein into your body, an mRNA vaccine injects genetic instructions.

Your cells read those instructions and build the target protein themselves — in the case of COVID-19, the spike protein. Your immune system sees the spike protein, raises an alarm, builds antibodies, and remembers it.

No actual virus involved. Just instructions.

What makes this interesting from a business perspective is the platform logic. Once you've figured out how to reliably deliver mRNA into cells — which is genuinely hard, involving lipid nanoparticles and cold chain logistics — you can theoretically make a medicine for almost anything.

You change the instruction, not the delivery system. Cancer, flu, HIV, rare genetic diseases.

It's like having a universal drug printer that just needs a new template.

Moderna makes money primarily from product sales — its COVID-19 vaccine, Spikevax, drove nearly all of its revenue from 2021 through 2023. The U.S.

government was its single biggest customer for years, under contracts worth billions. As COVID revenue has declined sharply, the company has been racing to diversify — pushing respiratory syncytial virus (RSV) vaccines, flu combinations, and cancer vaccines through clinical trials.

It also generates revenue from collaborative research agreements with larger pharma companies and from government funding for pandemic preparedness work.

The challenge now is that COVID essentially subsidized the entire platform buildout. Without that windfall, Moderna needs its pipeline to deliver — and that means navigating the brutal economics of drug development, where most things fail.

Spikevax is the flagship — Moderna's COVID-19 mRNA vaccine. It was authorized in the U.S.

in December 2020, just 11 months after the virus's genetic sequence was shared. Updated versions have followed each major variant.

It's been administered hundreds of millions of times globally and is the product that built the company's commercial infrastructure from scratch.

mRESVIA is Moderna's RSV vaccine, approved in the U.S. in May 2024 for adults 60 and older — its second-ever approved product and the first real test of its ability to compete in a crowded, established vaccine market.

The mRNA-4157/V940 cancer vaccine, developed with Merck, is the program the scientific community is watching most closely. It's a personalized cancer vaccine — each dose is custom-designed to target the specific mutations in an individual patient's tumor.

Early trial data in melanoma showed a 44% reduction in recurrence or death when combined with Keytruda. It's still in Phase 3.

If it works at scale, it would be one of the most significant advances in oncology in decades.

Moderna also has a combination flu-COVID vaccine in late-stage trials, as well as programs targeting cytomegalovirus (CMV), a herpes virus that causes serious complications in immunocompromised patients and newborns. The pipeline is deep.

The question is whether the company has the runway to see it through.

Moderna's growth strategy for most of its existence was the opposite of typical startup thinking: total secrecy, massive capital raises, and an absolute refusal to ship anything until the platform was ready. Flagship Pioneering kept the company in a near-hermetic information blackout through its first decade.

No products, no partnerships disclosed, no public proof points. Just fundraising and science.

The real break came from the U.S. government.

In 2020, Operation Warp Speed pumped nearly $1 billion into Moderna's COVID vaccine development — de-risking the manufacturing scale-up before anyone knew if the vaccine would work. That bet let Moderna move at a speed the private market never would have funded.

When the Phase 3 data came back in November 2020 showing 94.1% efficacy, the company went from 'interesting but unproven biotech' to 'we just helped end a pandemic' overnight.

The counterintuitive move was refusing to license the mRNA platform widely during the pandemic. While public pressure mounted, Moderna maintained control of its core IP — a decision that angered many but preserved its competitive moat for the long-term race against Pfizer-BioNTech and future mRNA competitors.

The second counterintuitive move was investing aggressively in its own manufacturing infrastructure instead of outsourcing — slower and more expensive upfront, but it gave them control over quality and supply that paid off enormously when demand exploded.

The cliff was visible from miles away, and Moderna still drove off it. COVID vaccine revenue peaked at $18.5 billion in 2021 and collapsed to under $2 billion by 2024 as demand dried up, contracts expired, and competition intensified.

The company went from printing money to burning it inside of two years. The pipeline — which the pandemic windfall was supposed to fund into commercialization — is still largely unproven.

Its RSV vaccine got approved in 2024, but it entered a market already occupied by GSK and Pfizer with established products.

The deeper problem is existential: Moderna is essentially a one-product company trying to become a multi-product platform company using technology that has still only ever produced one widely approved medicine. The mRNA cancer vaccine program, developed in partnership with Merck, is genuinely exciting science — but it's years from market.

The flu and combination respiratory programs face enormous competition. And the stock, which hit $497 in August 2021, fell below $60 by late 2024.

There's also the IP question. Moderna and Pfizer-BioNTech are locked in patent disputes over mRNA delivery technology.

The outcome could reshape royalty flows across the entire industry. And as COVID recedes from collective memory, the political will to fund pandemic preparedness — a key part of Moderna's government revenue strategy — is shaky at best.

Flagship Pioneering was the founding investor and architect — Noubar Afeyan's firm built Moderna from the ground up and remained its largest institutional shareholder for years. Flagship took an unusual role even by venture standards: it didn't just invest, it conceived and staffed the company.

That gave Moderna an unusually long leash to operate without external pressure to show results.

Before the IPO, Moderna raised over $3.2 billion in private funding. AstraZeneca signed a landmark collaboration agreement worth up to $240 million in 2013, lending enormous credibility to the mRNA platform at a time when most pharma companies were ignoring it.

Merck, Blackrock, and Fidelity were among later-stage investors. The company went public on NASDAQ in December 2018 at $23 per share — the largest biotech IPO in history at the time, raising $621 million before it had ever sold a product.

The U.S. government became arguably the most important capital partner.

Between BARDA contracts, Operation Warp Speed funding, and advance purchase agreements, the federal government committed billions to Moderna's COVID vaccine — essentially subsidizing the commercial-scale manufacturing buildout that transformed the company. DARPA had also funded early mRNA research years before, making this a rare case where public investment at multiple stages quietly enabled a private company's most profitable chapter.